



26 February 2009

Arana announces takeover discussions

Antibody therapeutics company Arana Therapeutics Ltd (ASX:AAH) refers to the trading halt requested this morning.

The company is presently in discussion with a third party regarding the possible takeover bid for Arana.

The Board advises that as discussions develop the company will make further announcements to the market.

About Arana Therapeutics:

Arana Therapeutics (ASX: AAH) is a biopharmaceutical company focused on developing next generation antibody based drugs that will improve the lives of patients with inflammatory diseases and cancer.

Arana Therapeutics' innovative engineering technologies provide the basis for developing its next generation antibody candidates. Arana Therapeutics has the financial strength and management expertise to develop its product pipeline.

Arana has a significant track record of commercialising its technologies and has collaborations with GlaxoSmithKline (GSK), CSL, Kyowa Hakko Kirin (KHK), and licensing arrangements with Centocor (J&J) and Abbott Laboratories.

For further information: www.arana.com

Contact information:

Company:
Steffen Nock
Acting CEO
Arana Therapeutics
T: + 61 2 8061 9900
E: snock@arana.com

Investor & Media Relations:
Paul Dekkers
Buchan Consulting
T: + 61 2 9237 2800
Mobile: 0418 218 722
E: pdekkers@bcg.com.au

Arana Therapeutics Limited
Level 2 37 Epping Road
Macquarie Park
Sydney, NSW 2113
Australia
P + 61 2 8061 9900
F + 61 2 8061 9999
ABN 98 002 951 877